The estimated Net Worth of Rachel E. Sherman is at least 183 千$ dollars as of 22 January 2020. Rachel Sherman owns over 2,174 units of Aptinyx Inc stock worth over 133$ and over the last 5 years he sold APTX stock worth over 0$. In addition, he makes 182,913$ as Independent Director at Aptinyx Inc.
Sign up
Rachel Sherman APTX stock SEC Form 4 insiders trading
Rachel has made over 1 trades of the Aptinyx Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,174 units of APTX stock worth 10,413$ on 22 January 2020.
The largest trade he's ever made was buying 2,174 units of Aptinyx Inc stock on 22 January 2020 worth over 10,413$. On average, Rachel trades about 435 units every 0 days since 2019. As of 22 January 2020 he still owns at least 2,174 units of Aptinyx Inc stock.
You can see the complete history of Rachel Sherman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rachel Sherman biography
Dr. Rachel E. Sherman M.D. serves as Independent Director of the Company. Dr. Sherman is a renowned expert in medical policy who served at the FDA for nearly 30 years until her retirement early in 2019. Most recently at the FDA, Dr. Sherman was the principal deputy commissioner — the commissioner's most senior policy advisor and the agency's highest position not politically appointed. Dr. Sherman held this position from 2017 until her retirement. Additional senior-level roles she held while at the FDA included deputy commissioner for Medical Products and Tobacco in the Office of the Commissioner and director of the Office of Medical Policy in the Center for Drug Evaluation and Research (CDER). During her time with the Agency, Dr. Sherman played lead roles in numerous policy and organizational initiatives credited with enhancing product development and facilitating patient access to innovative medicines, including expedited drug development and breakthrough therapy designation programs as well as the Opioid Policy Steering Committee. Dr. Sherman is currently president of Rachel Sherman Partners LLC, a drug development, regulatory, and policy consulting firm she founded in 2019 following her retirement from the FDA. She also serves as a clinical lecturer at Harvard Pilgrim Health Care Institute and as a senior policy fellow at Duke University's Margolis Center for Health Policy. Dr. Sherman received an A.B. in mathematics from Washington University (St. Louis), an M.D. from Mount Sinai School of Medicine, and an M.P.H. from The School of Hygiene and Public Health at Johns Hopkins University.
What is the salary of Rachel Sherman?
As the Independent Director of Aptinyx Inc, the total compensation of Rachel Sherman at Aptinyx Inc is 182,913$. There are 7 executives at Aptinyx Inc getting paid more, with Norbert Riedel having the highest compensation of 5,635,420$.
How old is Rachel Sherman?
Rachel Sherman is 62, he's been the Independent Director of Aptinyx Inc since 2019. There are 2 older and 8 younger executives at Aptinyx Inc. The oldest executive at Aptinyx Inc is Elisha Gould, 63, who is the Independent Director.
What's Rachel Sherman's mailing address?
Rachel's mailing address filed with the SEC is C/O APTINYX INC., 909 DAVIS STREET, SUITE 600, EVANSTON, IL, 60201.
Insiders trading at Aptinyx Inc
Over the last 6 years, insiders at Aptinyx Inc have traded over 0$ worth of Aptinyx Inc stock and bought 10,337,357 units worth 55,328,087$ . The most active insiders traders include Street Partners Llc Adams、Patrick G Enright、James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of 18,161$. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth 50,091$.
What does Aptinyx Inc do?
welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.
What does Aptinyx Inc's logo look like?
Complete history of Rachel Sherman stock trades at Aptinyx Inc
Aptinyx Inc executives and stock owners
Aptinyx Inc executives and other stock owners filed with the SEC include:
-
Norbert Riedel,
President, Chief Executive Officer, Director -
Ashish Khanna,
Chief Financial Officer, Chief Business Officer -
Andrew Kidd,
Chief Operating Officer -
Dr. Norbert G. Riedel,
Exec. Chairman -
Dr. Andrew D. Kidd B.M. B.Ch., M.D.,
CEO, Pres & Director -
Ashish Khanna,
CFO & Chief Bus. Officer -
Henry Gosebruch,
Independent Director -
Rachel Sherman,
Independent Director -
Robert Hombach,
Independent Director -
Patrick Enright,
Independent Chairman of the Board -
Adam Koppel,
Independent Director -
Elisha Gould,
Independent Director -
Tim Noffke,
VP of Program Management & Chief of Staff -
Dr. Harald Murck M.D., Ph.D.,
VP of Clinical & Medical Affairs -
Patrick Flavin,
Sr. Mang. of Corp. Devel. & Investor Relations -
Dr. Kathryn King Ph.D.,
Sr. VP of Clinical & CMC Operations -
Molly Dir,
VP of HR -
Juan Estupinan,
VP of Fin. & Accounting and Controller -
Capital Life Sciences Inves...,
-
Gilmore Neil O'neill,
-
Terry P Gould,
-
Leaf Venture Management Iii...,
-
David Houck,
Chief Development Officer -
Torsten M. Madsen,
Chief Medical Officer -
James N Topper,
Director -
Life Sciences Viii, L.P.Fhm...,
-
Capital Partners Ii, Llc Ta...,
-
Wilbur H Gantz,
Director -
Joseph R. Moskal,
Chief Scientific Officer -
Street Partners Llc Adams,
10% owner -
Liam Ratcliffe,
Director -
Joan W. Miller,